These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 17692845)
41. The Chromatin Modifier MSK1/2 Suppresses Endocrine Cell Fates during Mouse Pancreatic Development. Bhat N; Park J; Zoghbi HY; Arthur JS; Zaret KS PLoS One; 2016; 11(12):e0166703. PubMed ID: 27973548 [TBL] [Abstract][Full Text] [Related]
42. Chromatin remodeling and control of cell proliferation by progestins via cross talk of progesterone receptor with the estrogen receptors and kinase signaling pathways. Vicent GP; Ballaré C; Zaurin R; Saragüeta P; Beato M Ann N Y Acad Sci; 2006 Nov; 1089():59-72. PubMed ID: 17261755 [TBL] [Abstract][Full Text] [Related]
44. RhoA leads to up-regulation and relocalization of utrophin in muscle fibers. Gauthier-Rouvière C; Bonet-Kerrache A Biochem Biophys Res Commun; 2009 Jul; 384(3):322-8. PubMed ID: 19409875 [TBL] [Abstract][Full Text] [Related]
45. Programmable human histone phosphorylation and gene activation using a CRISPR/Cas9-based chromatin kinase. Li J; Mahata B; Escobar M; Goell J; Wang K; Khemka P; Hilton IB Nat Commun; 2021 Feb; 12(1):896. PubMed ID: 33563994 [TBL] [Abstract][Full Text] [Related]
46. Increased histone H3 phosphorylation in neurons in specific brain structures after induction of status epilepticus in mice. Mori T; Wakabayashi T; Ogawa H; Hirahara Y; Koike T; Yamada H PLoS One; 2013; 8(10):e77710. PubMed ID: 24147063 [TBL] [Abstract][Full Text] [Related]
47. [The regulation of UTROPHIN expression by EN1]. Wang Q; Cao DH; Lin CK; Wang ZD; Cui WT; Jin CL Yi Chuan; 2011 Apr; 33(4):347-52. PubMed ID: 21482524 [TBL] [Abstract][Full Text] [Related]
48. Using utrophin to treat DMD. Nat Rev Drug Discov; 2019 Nov; 18(12):904. PubMed ID: 31780847 [No Abstract] [Full Text] [Related]
49. Endogenous bioluminescent reporters reveal a sustained increase in utrophin gene expression upon EZH2 and ERK1/2 inhibition. Gleneadie HJ; Fernandez-Ruiz B; Sardini A; Van de Pette M; Dimond A; Prinjha RK; McGinty J; French PMW; Bagci H; Merkenschlager M; Fisher AG Commun Biol; 2023 Mar; 6(1):318. PubMed ID: 36966198 [TBL] [Abstract][Full Text] [Related]
50. Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies. Soblechero-Martín P; López-Martínez A; de la Puente-Ovejero L; Vallejo-Illarramendi A; Arechavala-Gomeza V Neuropathol Appl Neurobiol; 2021 Oct; 47(6):711-723. PubMed ID: 33999469 [TBL] [Abstract][Full Text] [Related]
51. Chemical Proteomics and Phenotypic Profiling Identifies the Aryl Hydrocarbon Receptor as a Molecular Target of the Utrophin Modulator Ezutromid. Wilkinson IVL; Perkins KJ; Dugdale H; Moir L; Vuorinen A; Chatzopoulou M; Squire SE; Monecke S; Lomow A; Geese M; Charles PD; Burch P; Tinsley JM; Wynne GM; Davies SG; Wilson FX; Rastinejad F; Mohammed S; Davies KE; Russell AJ Angew Chem Int Ed Engl; 2020 Feb; 59(6):2420-2428. PubMed ID: 31755636 [TBL] [Abstract][Full Text] [Related]
52. Do porcine Sertoli cells represent an opportunity for Duchenne muscular dystrophy? Chiappalupi S; Salvadori L; Luca G; Riuzzi F; Calafiore R; Donato R; Sorci G Cell Prolif; 2019 May; 52(3):e12599. PubMed ID: 30912260 [TBL] [Abstract][Full Text] [Related]